Identification of Virulence Markers and Phylogenetic Groups' Association, and Antimicrobial Susceptibility of Uropathogenic Escherichia coli Isolates.

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526522666220908161529

Dahbia Yasmina Meziani, Nicolas Barnich, Anouar Boucheham, Mohamed Larbi Rezgoune, Kaddour Benlabed, Michael Rodrigues, Dalila Satta

{"title":"Identification of Virulence Markers and Phylogenetic Groups' Association, and Antimicrobial Susceptibility of Uropathogenic <i>Escherichia coli</i> Isolates.","authors":"Dahbia Yasmina Meziani, Nicolas Barnich, Anouar Boucheham, Mohamed Larbi Rezgoune, Kaddour Benlabed, Michael Rodrigues, Dalila Satta","doi":"10.2174/1871526522666220908161529","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nUrinary tract infections represent a world public health problem, which is caused mainly by Uropathogenic Escherichia coli. Although, they are originally found in the intestinal microbiota in the majority of the cases, urinary tract infections can also be caused by intra-intestinal pathogenic E. coli.\n\n\nOBJECTIVE\nThe main objective of our research is to identify the virulence factors generally associated with different pathotypes across phylogenetic groups.\n\n\nMETHODS\nE. coli were isolated from patients with urinary tract infections. Antimicrobial susceptibility tests, virulence genes and phylogroups were prospected. The data analysis were performed using the chi-square and Fisher exact test.\n\n\nRESULTS\nIn total, 72.2% of isolates were showed multidrug resistant. We have also depicted an important association between E. coli from inpatients with UTIs and pap and hlyA genes (p-0.041 and p-0.019 respectively). The predominant phylogenetic group in our isolates is B2 (45.4%) followed by D (12.4%). Our results showed that 9.3% of isolates have an unknown phylogroup which show a significant association with astA gene (p-0.008). We have as well find a significant association between B2 and three virulence genes namely pap, hlyA and invE (p-0.002, p-0.001, p-0.025 respectively); B1 and pap, hlyA genes (p-0.049 and p-0.021 respectively); E and afa gene (p-0.024).\n\n\nCONCLUSION\nCertain virulence factors have been shown to be potential targets for drug design and therapeutic pathways in order to deal with the antimicrobial resistance problem enhanced by antibiotic therapy.","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526522666220908161529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Urinary tract infections represent a world public health problem, which is caused mainly by Uropathogenic Escherichia coli. Although, they are originally found in the intestinal microbiota in the majority of the cases, urinary tract infections can also be caused by intra-intestinal pathogenic E. coli. OBJECTIVE The main objective of our research is to identify the virulence factors generally associated with different pathotypes across phylogenetic groups. METHODS E. coli were isolated from patients with urinary tract infections. Antimicrobial susceptibility tests, virulence genes and phylogroups were prospected. The data analysis were performed using the chi-square and Fisher exact test. RESULTS In total, 72.2% of isolates were showed multidrug resistant. We have also depicted an important association between E. coli from inpatients with UTIs and pap and hlyA genes (p-0.041 and p-0.019 respectively). The predominant phylogenetic group in our isolates is B2 (45.4%) followed by D (12.4%). Our results showed that 9.3% of isolates have an unknown phylogroup which show a significant association with astA gene (p-0.008). We have as well find a significant association between B2 and three virulence genes namely pap, hlyA and invE (p-0.002, p-0.001, p-0.025 respectively); B1 and pap, hlyA genes (p-0.049 and p-0.021 respectively); E and afa gene (p-0.024). CONCLUSION Certain virulence factors have been shown to be potential targets for drug design and therapeutic pathways in order to deal with the antimicrobial resistance problem enhanced by antibiotic therapy.

查看原文本刊更多论文

尿路致病性大肠杆菌毒力标记、系统进化群关联及药敏研究。

背景:尿路感染是一个世界性的公共卫生问题，主要由尿路致病性大肠杆菌引起。虽然在大多数情况下，它们最初是在肠道微生物群中发现的，但尿路感染也可能由肠道内致病性大肠杆菌引起。目的:我们研究的主要目的是确定与不同系统发育群不同病理类型相关的毒力因子。方法:从尿路感染患者中分离大肠杆菌。对其药敏试验、毒力基因和系统群进行了展望。数据分析采用卡方检验和Fisher精确检验。结果:72.2%的分离株出现多重耐药。我们还描述了尿路感染住院患者的大肠杆菌与pap和hlyA基因之间的重要关联(分别为p-0.041和p-0.019)。系统发育类群以B2(45.4%)居多，其次为D(12.4%)。结果显示，9.3%的分离株具有未知的系统群，该系统群与astA基因显著相关(p-0.008)。我们还发现B2与pap、hlyA和invE三个毒力基因显著相关(分别为p-0.002、p-0.001和p-0.025);B1和pap、hlyA基因(p-0.049和p-0.021);E和afa基因(p-0.024)。结论:某些毒力因子已被证明是药物设计和治疗途径的潜在靶点，以解决抗生素治疗增加的耐药性问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.